Show simple item record

AuthorAshour, A.A.
AuthorAtta, M.A.
AuthorSadek, K.W.
AuthorObaid, K.R.
AuthorAshour, M.A.
AuthorAshour, A.
AuthorDanjuma, M.I.
AuthorDoi, S.A.
AuthorElzouki, A.-N.
Available date2022-04-18T08:10:55Z
Publication Date2021
Publication NameEuropean Journal of Gastroenterology and Hepatology
ResourceScopus
Identifierhttp://dx.doi.org/10.1097/MEG.0000000000001932
URIhttp://hdl.handle.net/10576/29973
AbstractEnd-stage liver disease and its related complications exert a huge disease burden and reduce the survival rates of many patients. Albumin administration for patients with decompensated liver cirrhosis has been a controversial topic of discussion. The aim of this study is to investigate whether albumin reduces the mortality and complications of liver cirrhosis compared to standard medical therapy (SMT) alone. Clinical trials in which albumin administration was compared to SMT in patients with liver cirrhosis were included in this meta-analysis. The primary outcome of this study was to evaluate the effect on reducing all-cause mortality. Ascites control, renal failure and hepatic encephalopathy were evaluated as secondary outcomes. Nine clinical trials with 1231 patients were recruited and analyzed using the quality effect model. Mortality rate was significantly reduced in the albumin group [relative risk (RR) 0.73, 95% confidence interval (CI) 0.56-0.96]. Heterogeneity was mild across all studies (I223.3%). Studies reporting long-term albumin (LTA) administration were found to have a significant decrease in mortality (RR 0.57, 95% CI 0.44-0.73). However, studies reporting short-term albumin administration were found to have no effect on mortality (RR 0.90, 95% CI 0.56-1.45). Furthermore, there was a significant decrease in the incidence of all secondary outcomes. This meta-analysis provides evidence that LTA administration is significantly effective in reducing the mortality of liver cirrhosis compared to SMT. Albumin administration was also shown to reduce the occurrence of ascites, renal failure and hepatic encephalopathy as complications of liver cirrhosis.
Languageen
PublisherLippincott Williams and Wilkins
Subjectalbuminoid
ascites
hepatic encephalopathy
human
liver cirrhosis
meta analysis
survival rate
Albumins
Ascites
Hepatic Encephalopathy
Humans
Liver Cirrhosis
Survival Rate
TitleAlbumin administration in patients with decompensated liver cirrhosis: A meta-analytic update
TypeArticle Review
Pagination479-486
dc.accessType Abstract Only


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record